191 related articles for article (PubMed ID: 29203817)
21. The Dual Role of Autophagy in Crizotinib-Treated ALK
Espinos E; Lai R; Giuriato S
Cells; 2021 Sep; 10(10):. PubMed ID: 34685497
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of CREB binding protein-beta-catenin signaling down regulates CD133 expression and activates PP2A-PTEN signaling in tumor initiating liver cancer cells.
Tang Y; Berlind J; Mavila N
Cell Commun Signal; 2018 Mar; 16(1):9. PubMed ID: 29530069
[TBL] [Abstract][Full Text] [Related]
23. Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.
Fontana D; Ceccon M; Gambacorti-Passerini C; Mologni L
Cancer Med; 2015 Jul; 4(7):953-65. PubMed ID: 25727400
[TBL] [Abstract][Full Text] [Related]
24. The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/beta-catenin pathway.
Flahaut M; Meier R; Coulon A; Nardou KA; Niggli FK; Martinet D; Beckmann JS; Joseph JM; Mühlethaler-Mottet A; Gross N
Oncogene; 2009 Jun; 28(23):2245-56. PubMed ID: 19421142
[TBL] [Abstract][Full Text] [Related]
25. ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors.
Lovisa F; Cozza G; Cristiani A; Cuzzolin A; Albiero A; Mussolin L; Pillon M; Moro S; Basso G; Rosolen A; Bonvini P
PLoS One; 2015; 10(4):e0121378. PubMed ID: 25874976
[TBL] [Abstract][Full Text] [Related]
26. Revealing Acquired Resistance Mechanisms of Kinase-Targeted Drugs Using an on-the-Fly, Function-Site Interaction Fingerprint Approach.
Zhao Z; Bourne PE
J Chem Theory Comput; 2020 May; 16(5):3152-3161. PubMed ID: 32283024
[TBL] [Abstract][Full Text] [Related]
27. SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors.
Dardaei L; Wang HQ; Singh M; Fordjour P; Shaw KX; Yoda S; Kerr G; Yu K; Liang J; Cao Y; Chen Y; Lawrence MS; Langenbucher A; Gainor JF; Friboulet L; Dagogo-Jack I; Myers DT; Labrot E; Ruddy D; Parks M; Lee D; DiCecca RH; Moody S; Hao H; Mohseni M; LaMarche M; Williams J; Hoffmaster K; Caponigro G; Shaw AT; Hata AN; Benes CH; Li F; Engelman JA
Nat Med; 2018 May; 24(4):512-517. PubMed ID: 29505033
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of anaplastic lymphoma kinase promotes apoptosis and suppresses proliferation in human hepatocellular carcinoma.
Yu Z; Zhao R
Anticancer Drugs; 2018 Jul; 29(6):513-519. PubMed ID: 29570100
[TBL] [Abstract][Full Text] [Related]
29. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
30. Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors.
Ceccon M; Mologni L; Bisson W; Scapozza L; Gambacorti-Passerini C
Mol Cancer Res; 2013 Feb; 11(2):122-32. PubMed ID: 23239810
[TBL] [Abstract][Full Text] [Related]
31. Crizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibition.
Megiorni F; McDowell HP; Camero S; Mannarino O; Ceccarelli S; Paiano M; Losty PD; Pizer B; Shukla R; Pizzuti A; Clerico A; Dominici C
J Exp Clin Cancer Res; 2015 Oct; 34():112. PubMed ID: 26445453
[TBL] [Abstract][Full Text] [Related]
32. Targeting stemness is an effective strategy to control EML4-ALK+ non-small cell lung cancer cells.
Oh SJ; Noh KH; Lee YH; Hong SO; Song KH; Lee HJ; Kim S; Kim TM; Jeon JH; Seo JH; Kim DW; Kim TW
Oncotarget; 2015 Nov; 6(37):40255-67. PubMed ID: 26517679
[TBL] [Abstract][Full Text] [Related]
33. Combined Inhibition of ALK and HDAC Induces Synergistic Cytotoxicity in Neuroblastoma Cell Lines.
Hagiwara K; Tokunaga T; Iida H; Nagai H
Anticancer Res; 2019 Jul; 39(7):3579-3584. PubMed ID: 31262882
[TBL] [Abstract][Full Text] [Related]
34. Exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer.
Morcos PN; Nueesch E; Jaminion F; Guerini E; Hsu JC; Bordogna W; Balas B; Mercier F
Cancer Chemother Pharmacol; 2018 Jul; 82(1):129-138. PubMed ID: 29748847
[TBL] [Abstract][Full Text] [Related]
35. Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.
Krytska K; Ryles HT; Sano R; Raman P; Infarinato NR; Hansel TD; Makena MR; Song MM; Reynolds CP; Mossé YP
Clin Cancer Res; 2016 Feb; 22(4):948-60. PubMed ID: 26438783
[TBL] [Abstract][Full Text] [Related]
36. Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma.
Pacenta HL; Macy ME
Drug Des Devel Ther; 2018; 12():3549-3561. PubMed ID: 30425456
[TBL] [Abstract][Full Text] [Related]
37. Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma.
Mitou G; Frentzel J; Desquesnes A; Le Gonidec S; AlSaati T; Beau I; Lamant L; Meggetto F; Espinos E; Codogno P; Brousset P; Giuriato S
Oncotarget; 2015 Oct; 6(30):30149-64. PubMed ID: 26338968
[TBL] [Abstract][Full Text] [Related]
38. Background and rationale of the eXalt3 trial investigating X-396 in the treatment of ALK+ non-small-cell lung cancer.
Singhi EK; Horn L
Future Oncol; 2018 Aug; 14(18):1781-1787. PubMed ID: 29506392
[TBL] [Abstract][Full Text] [Related]
39. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.
Croegaert K; Kolesar JM
Am J Health Syst Pharm; 2015 Sep; 72(17):1456-62. PubMed ID: 26294238
[TBL] [Abstract][Full Text] [Related]
40. Crizotinib induces apoptosis and gene expression changes in ALK+ anaplastic large cell lymphoma cell lines; brentuximab synergizes and doxorubicin antagonizes.
Hudson S; Wang D; Middleton F; Nevaldine BH; Naous R; Hutchison RE
Pediatr Blood Cancer; 2018 Aug; 65(8):e27094. PubMed ID: 29697184
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
